Personalized Drug Therapy Key Laboratory of Sichuan Province, Department of Pharmacy, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, 610072, Chengdu, China.
Department of Ultrasonic, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, 610072, Chengdu, China.
Signal Transduct Target Ther. 2020 Sep 23;5(1):213. doi: 10.1038/s41392-020-00315-3.
Protein-protein interactions (PPIs) have pivotal roles in life processes. The studies showed that aberrant PPIs are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. Therefore, targeting PPIs is a direction in treating diseases and an essential strategy for the development of new drugs. In the past few decades, the modulation of PPIs has been recognized as one of the most challenging drug discovery tasks. In recent years, some PPIs modulators have entered clinical studies, some of which been approved for marketing, indicating that the modulators targeting PPIs have broad prospects. Here, we summarize the recent advances in PPIs modulators, including small molecules, peptides, and antibodies, hoping to provide some guidance to the design of novel drugs targeting PPIs in the future.
蛋白质-蛋白质相互作用（PPIs）在生命过程中起着关键作用。研究表明，异常的蛋白质-蛋白质相互作用与各种疾病有关，包括癌症、传染病和神经退行性疾病。因此，靶向蛋白质-蛋白质相互作用是治疗疾病的一个方向，也是开发新药的重要策略。在过去的几十年中，蛋白质-蛋白质相互作用的调节已被认为是最具挑战性的药物发现任务之一。近年来，一些蛋白质-蛋白质相互作用调节剂已进入临床研究，其中一些已获得批准上市，这表明靶向蛋白质-蛋白质相互作用的调节剂具有广阔的前景。在这里，我们总结了蛋白质-蛋白质相互作用调节剂的最新进展，包括小分子、肽和抗体，希望为未来靶向蛋白质-蛋白质相互作用的新型药物设计提供一些指导。
